From α-Synuclein Pathology to Practice: Understanding Parkinson's Disease Through Luk et al. (2012)

Authors

  • Mofei Sun

DOI:

https://doi.org/10.54097/cjdczh39

Keywords:

Parkinson's Disease, α-synuclein, Lewy Bodies, Prion-like Transmission, Immunohistochemistry, Neurodegeneration, Preformed Fibrils

Abstract

Parkinson's disease (PD) is the second most common type of neurodegenerative disorder; it is characterized by broken motor functions and the buildup of the α-synuclein protein into Lewy bodies. The 2012 study from Luk and colleagues changed how PD pathology is understood, demonstrating the synthetic forms of the pre-fibrils of α-synuclein protein can prompt a complete neurodegenerative cascade in the wild type mice through a mechanism of prion like transmission. This review analyses the current understanding of the structures of the α-synuclein protein, how the protein aggregates and the formation of Lewy bodies. We discuss as well the evidence supporting the prion-like hypothesis of the progression of the disease. We discuss the fibril constructions' dorsal striatum of the mice's dorsal nuclear fibrils, and the nontransgenic mice's dorsal striatum's dorsal nuclear fibrils, and in the fibril constructions' dorsal striatum's nontransgenic mice dorsal Striatum's fibrils dorsal nuclear the dorsal Striatum's nontransgenic mice fibrils, dorsal Striatum, nontransgenic mice. The immuno-therapy. As well, the biomedical guidelines the brain areas, degeneration of brain areas, and the LD-like degeneration of the dorsal Striatum, compartments of the dorsal Striatum's compartments, the compartments'entre eux compartments, the compartments of the compartments of Striatum.

Downloads

Download data is not yet available.

References

[1] Tofaris, G. K. (2022). Initiation and progression of α-synuclein pathology in Parkinson’s disease. Cellular and molecular life sciences, 79(4), 210.

[2] Espay, A. J., & Lees, A. J. (2025). Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research. Movement Disorders Clinical Practice.

[3] Alafuzoff, I., Parkkinen, L., Al-Sarraj, S., Arzberger, T., Bell, J., Bodi, I., ... & Kretzschmar, H. (2008). Assessment of α-synuclein pathology: a study of the BrainNet Europe Consortium. Journal of Neuropathology & Experimental Neurology, 67(2), 125-143.

[4] Park, H., Kam, T. I., Dawson, V. L., & Dawson, T. M. (2025). α-Synuclein pathology as a target in neurodegenerative diseases. Nature Reviews Neurology, 21(1), 32-47.

[5] Henderson, M. X., Trojanowski, J. Q., & Lee, V. M. Y. (2019). α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neuroscience letters, 709, 134316.

[6] Burré, J., Sharma, M., & Südhof, T. C. (2018). Cell biology and pathophysiology of α-synuclein. Cold Spring Harbor perspectives in medicine, 8(3), a024091.

Downloads

Published

27-03-2026

Issue

Section

Articles

How to Cite

Sun, M. (2026). From α-Synuclein Pathology to Practice: Understanding Parkinson’s Disease Through Luk et al. (2012). International Journal of Biology and Life Sciences, 13(3), 153-155. https://doi.org/10.54097/cjdczh39